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Abstract:   
Though weight gain is a common side effect of antipsychotic treatment, there are 
no useful predictors of which patients are likely to be affected and to what de-
gree. It has been shown that exposure to adverse conditions during intra-uterine 
life confers a vulnerability to the development of later life metabolic complications 
and low birth weight for gestational age has been shown to be a robust marker of 
such prenatal adversity. We hypothesized that patients with schizophrenia with a 
lower birth weight will have increased vulnerability to the weight inducing effects 
of antipsychotic treatment. The relationship between birth weight and total and 
central adiposity, measured as body mass index (BMI) and waist-to-hip ratio 
(WHR) respectively, was examined in three groups: drug naïve first episode of 
psychosis (FEP) patients (n=41), treatment resistant schizophrenia (TRS) pa-
tients (n=42) and matched healthy volunteers (n=72). All analyses were con-
trolled for age, gender and duration of treatment exposure. We found that a lower 
birth weight was associated with higher BMI and WHR only in TRS patients but 
not in FEP or controls, suggesting that prenatal adversity, as indicated by the 
surrogate marker of a lower birth weight, confers an increased vulnerability to 
clozapine induced weight gain.  
 
 
 
Key words:  Birth weight, developmental programming, clozapine, schizophre-
nia, weight gain, first episode psychosis. 
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Introduction 
Up to 75% of patients taking antipsychotic for schizophrenia gain excessive 
weight (NICE, 2014). This has important implications for treatment compliance 
and health of a patient group that already has an average life expectancy 16-25 
years less than the general population (Saha et al., 2007). A major limitation is 
the paucity of effective treatments for this weight gain or reliable predictors of 
who is more likely to gain weight on these treatments and to what degree 
(Fernandez-Egea et al., 2011). 
Low birth weight for gestational age, a surrogate marker of intra-utero growth 
stress, is a risk factor common to both schizophrenia (Cannon et al., 2002) and 
metabolic disease (Cottrell and Ozanne, 2008). Studies of the Dutch Hunger 
Winter and the Chinese famine showed that individuals who experienced caloric 
deprivation during intra-uterine life, and consequently were born with low birth 
weight, were at greater risk for developing both metabolic disorders and schizo-
phrenia (Susser and St Clair, 2013). The role of suboptimal prenatal environment 
in the development of metabolic and cardiovascular disease has been extensive-
ly studied and it is now widely recognised that adversity during fetal life, caused 
by for example placental insufficiency or maternal malnutrition, triggers various 
fetal adaptations as a predictive adaptive response in anticipation of similar con-
ditions in postnatal life (Hales and Barker, 2001). These include the sparing of 
vital organs such as the brain at the expense of other organs such as the pan-
creas, and are protective for immediate postnatal survival and remain so if the 
postnatal environment is similar (Barnes and Ozanne, 2011). While the individual 
may have small abnormalities in the cardiovascular and metabolic systems such 
as mildly elevated blood pressure or impaired glucose tolerance, it is 
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when the postnatal environment does not match the predicted one, for example 
with widespread availability of calorie rich food, that these adaptations increase 
the risk for the development of obesity, type 2 diabetes and hypertension.  
While this model has been extensively studied in animal models and human pop-
ulation studies (Bann et al., 2014; Eriksson et al., 2001), there has been little ex-
ploration of the possible association of schizophrenia and obesity as part of a 
shared developmental programming effect (Garcia-Rizo et al., 2014). Subtle 
metabolic abnormalities such as glucose dysregulation (Fernandez-Egea et al., 
2009) and increased intra-abdominal fat (Thakore et al., 2002) have been de-
scribed in drug naive psychotic patients, and these would be consistent with such 
a programming effect.  
We hypothesized that in schizophrenia, birth weight is a marker of a vulnerability 
to weight gain and metabolic complications (See Figure 1). This vulnerability in-
teracts with an environmental factor, namely antipsychotic treatment, resulting in 
the development of excessive adiposity in those individuals with a lower birth 
weight. To test this hypothesis, we examined two patient groups with schizophre-
nia and a matched healthy control group. The two patient groups were treatment 
naive first episode non-affective psychosis patients (with diagnosis, no treatment) 
and treatment resistant patients (with diagnosis, on treatment) on clozapine, 
which has one of the highest propensities to induce weight gain, second only to 
olanzapine (Leucht et al., 2013). Our aim was to examine if birth weight modulat-
ed the degree of development of weight gain in response to antipsychotic treat-
ment. 
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Experimental Procedures 
The study was conducted using data from two clinical databases described else-
where, the 'Diabetes in neuropsychiatric disorders' database for drug naive first 
episode psychosis (FEP) patients at Hospital Clinic in Barcelona, Spain 
(Fernandez-Egea et al., 2009), and the ‘Clinical and Research Database in Per-
sistent Schizophrenia’ in the Cambridgeshire and Peterborough Foundation NHS 
Trust Mental Health in the UK (www.psychiatry.cam.ac.uk/f20). Informed consent 
was taken from participants prior to inclusion in the databases. Ethical approval 
to collect the patient data was granted by the Hospital Clinic Ethics Committee 
(Barcelona) and the NRES Cambridge Central Research Ethics Committee 
(13/EE/0121).  
Birth weight was collected as part of the study protocol for the FEP patients and 
clinical routine practice for TRS patients. Birth weight data were self-reported and 
only included if verified by a parent or if the patient reported the same birth 
weight at a minimum of two separate consultations. All participants from the two 
databases for whom a reliable birth weight was available were included and this 
was the only inclusion criterion. Clinical and anthropometric data were collected 
from the research project for the FEP and healthy control groups and the clinical 
notes and routine physical monitoring that all TRS patients undergo. Data on sex, 
age, height, current weight and waist and hip circumference, were collected on all 
individuals by observers blind to the status of the birth weigh information. Body 
Mass Index (BMI) and waist-to-hip ratio (WHR) were derived from the anthropo-
metric data. All subjects had data on either BMI or WHR. The included partici-
pants did not differ from those on whom no birth weight data were available in 
terms of their BMI or WHR. For the TRS patients data on the duration and 
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dose of antipsychotic treatment, use of other drugs affecting weight (e.g. 
mirtazapine), known metabolic complications and smoking status, were obtained 
from the clinical notes. All TRS patients were on clozapine with the exception of 
one on high-dose olanzapine.  
Statistical Analyses: All analyses were carried out using linear regression (lm 
package in R). The primary analyses tested the hypothesis that the relationship 
between birth weight and adult adiposity would only be seen in patients exposed 
to antipsychotic treatment. The model included birth weight, group and a birth 
weight x group interaction. The group variable contains the treatment effect: con-
trols (no diagnosis, no treatment), FEP (diagnosis present, no treatment) and 
TRS (diagnosis present, treatment present). However FEP and TRS groups may 
vary in other respects so the group variable was coded as a factor with 3 levels 
and not as a continuous variable as this approach makes fewer assumptions 
about the relationship between the groups. Treatment duration, age and gender 
were included as covariates as the groups differed significantly in terms of age 
and the sample had more males than females. Treatment duration was chosen 
as the measure of total antipsychotic exposure and calculated as the total dura-
tion of treatment from the first initiation of antipsychotic treatment. The primary 
analyses were carried out separately for the dependent variables of BMI and 
WHR and a Bonferroni correction was applied.  
Two secondary analyses were carried out in the TRS group alone. In the primary 
analyses the TRS factor includes both diagnosis and treatment variables and it is 
not possible to separate these. To explore this further the secondary analyses 
examined the relationship between birth weight and the adiposity measures after 
controlling for treatment exposure (treatment duration). Age, gender and 
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smoking status (associated with lower clozapine plasma levels) were included as 
covariates and BMI and WHR were examined as separate dependent variables 
and a Bonferroni correction was applied.  
 
Results 
The final sample included only subjects on whom reliable data on birth weight 
was available. This included 41 drug naive FEP patients from Barcelona (out of 
92 included in the database), 42 individuals with TRS from the UK (out of 152 
patients) and 72 healthy controls from both UK and Spain (out of 135 recruited). 
The overall sample characteristics are shown in Table 1.  
There was a strong correlation between BMI and WHR across the whole sample 
(r =0.59, p<0.0001). The correlation between age and birth weight was examined 
to check for potential collinearity and was found to be nonsignificant (r=0.11, 
p=0.17). After controlling for age, sex and treatment duration, there was a signifi-
cant effect of TRS group status on BMI (T=6.06, p<0.0001), with TRS status be-
ing associated with higher BMI. There was a significant negative TRS group x 
birth weight interaction (T=-3.78,p=0.0002) i.e. a unit increase in birth weight pro-
duces a corresponding decrease in adult BMI. For the WHR analysis, there was 
a significant effect of TRS group (T=2.88, p=0.0046) but the birth weight x treat-
ment interaction term did not reach significance (T=-1.72,p=0.087). The signifi-
cant effect of TRS group status was investigated further in the secondary anal-
yses. Lower birth weight in TRS patients was significantly associated with greater 
BMI (T=-2.38,p=0.023) and WHR (T=-2.51,p=0.017). These associations re-
mained even if the one TRS patient on high dose olanzapine was removed from 
the sample. There was no effect of smoking status on these associations.  
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Discussion 
We found that a lower birth weight was significantly associated with adiposity in 
TRS patients. This association was not found in drug naive patients and healthy 
volunteers, suggesting that the metabolic consequences of developmental pro-
gramming only become grossly apparent after exposure to an additional insult, in 
this case antipsychotic treatment, and it modulates the degree of weight gain and 
fat distribution in response to the treatment.  
We hypothesized that in schizophrenia, antipsychotic treatment represented the 
key environmental factor that interacts with this vulnerability, especially as it is like-
ly that all individuals in the current study will already have had a significant exposure to a 
similar environment (occidental caloric rich food environment).. In our study there was 
no difference in birth weight between the three groups. There was no effect of 
lower birth weight on adiposity in un-medicated individuals (controls and FEP 
patients). In these groups BMI and WHR were associated with age and gender 
but it is only in the TRS group that we saw an effect of a lower birth weight, sug-
gesting that antipsychotic medication may be the environmental factor that un-
masks this vulnerability. 
Our findings are novel in the field of schizophrenia, but are in line with a large 
body of evidence in metabolic science that shows that low birth weight (as a 
marker of prenatal adversity) is associated with later life obesity and metabolic 
disease, especially when associated with a second “hit” such as postnatal over-
nutrition (Ozanne et al., 2004). Patients with schizophrenia treated with antipsy-
chotics represent a particular case in this model of obesity with intra-
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uterine stressors conferring vulnerability to developing both schizophrenia and 
metabolic complications, with both conditions probably developing in response to 
additional factors. Recent evidence shows that severe prenatal stress in mice 
confers vulnerability for developing both metabolic and neural disturbances, the 
latter manifest as abnormalities in prepulse inhibition (PPI) abnormalities, a pre-
attentive process known to be impaired in schizophrenia (Pacheco-Lopez et al., 
2011). Subtle metabolic abnormalities have been described in schizophrenia in 
drug naive patients, such as increased visceral fat (Thakore et al., 2002) or 
prediabetes (Fernandez-Egea et al., 2009). Interestingly, these are subclinical 
abnormalities that were only observed when using more precise tools (such as 
CT scan or glucose tolerance tests). This is in keeping with the idea that they 
represent vulnerability traits rather than overt disorders.   
Our findings add to the accumulating evidence suggesting that a lower birth 
weight is not only a risk factor for developing schizophrenia (Cannon et al., 2002) 
but is also associated with a poorer prognosis. Low birth weight is a predictor of 
poorer cognitive functioning (Torniainen et al., 2013); it has been associated with 
smaller cortical area (Haukvik et al., 2014), more severe clinical symptomatology 
and attentional impairment (Wegelius et al., 2013). This cross-sectional study 
cannot adequately address this. While the distribution of birth weight in the three 
groups is very similar, there is the possibility that patients with first episode psy-
chosis with a lower birth weight may go on to develop a more severe form of the 
illness. However what we do find is that even if we consider only patients who 
have reached the stage of treatment resistance, there is a clear relationship be-
tween a lower birth weight and adiposity. 
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Our results also suggest that birth weight might be a useful predictor of antipsy-
chotic induced weight gain. A more comprehensive model should include genetic 
(Shungin et al., 2015) as well as neurodevelopmental information (birth weight), 
environmental factors (i.e. antipsychotic medication), and behavioural factors (i.e. 
sedentarism). Birth weight could be a rapidly accessible measure than could help 
clinicians to predict who will be at greater risk for weight gain and/or will need 
more regular physical health checks. However a larger longitudinal study will be 
required to provide a more robust quantification of the effect of birth weight on 
future weight gain that could be used reliably in the clinic. It would also be im-
portant to examine if this effect is seen with other antipsychotics apart from 
clozapine.  
We acknowledge some limitations to our study. Lower birth weight was consid-
ered exclusively as a surrogate marker of intra-utero stress, but this is not the 
only possible cause of low birth weight. We did not examine the potential role of  
adverse childhood experiences and this might require further study in the future. 
The sample size is relatively small and the main dependent variable was ob-
tained by self-report. However, where possible the birth weight data were corrob-
orated by collateral history from a parent and in all other instances data were only 
included if the self-report was consistent across a minimum of two consultations. 
Importantly, birth weight data were collected in the same way for all 3 groups. 
There was a significant age difference between the TRS and the other groups 
and while we controlled for age in all analyses, given the difference in age distri-
bution across the groups, its contribution cannot be reliably determined by co-
varying for it in our statistical models. However, the effect of birth weight on adi-
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posity in the TRS group was seen in total fat (BMI) and also in the central fat dis-
tribution (WHR), being the latter being less associated with age. Duration of 
treatment exposure is an important factor in these analyses. Ideally one should 
examine total cumulative antipsychotic exposure but we did not have sufficient 
data from clinical records or clozapine plasma levels to estimate this. We there-
fore calculated treatment exposure as the time from first initiation of antipsychotic 
to the present. This variable does not account for dosage, periods of non-
compliance or treatment cessation and does not capture the number of different 
drugs prescribed. However for the purposes of this analysis it is likely to exag-
gerate the effect of antipsychotic treatment (i.e. as per the variable all individuals 
have been on clozapine for their entire treatment history) in the models and re-
duces the chances of detecting a birth weight effect. This variable also captures 
duration of illness and assumes that individuals have been continuously ill since 
first initiation of treatment. Given that we are studying a trait and not state vulner-
ability, we believe that this is a reasonable assumption. Finally, the study is 
cross-sectional as a prospective longitudinal study to test these hypotheses 
would be extremely challenging to carry out, as it should ideally include drug na-
ive patients followed up for a number of years. Nevertheless the limitations of 
cross-sectional designs remain but replication of this association in larger sam-
ples such as well-described cohorts would help corroborate our findings.   
In conclusion, our study suggests that birth weight, as a measure of intra-uterine 
adversity, modulates the susceptibility to antipsychotic induced weight gain. 
Though one must be cautious given the small sample size and cross-sectional 
design of this study, it does accord with the paradigm that considers schizophre-
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nia not just as a brain disorder but also as a whole body-disease (Khandaker et 
al., 2014; Kirkpatrick et al., 2014). Indeed early life stress been theoretically de-
scribed as a risk factor for both, mental and metabolic disorders over time, in this 
model metabolic disturbances are a constitutive part of the disorder (Garcia-Rizo 
et al., 2014), expressed at a later stage but earlier than the general population 
(Kirkpatrick et al., 2008). This might also help revise our interpretation of the early 
morbidity and mortality associated with schizophrenia (Laursen et al., 2014) and 
promote the use of secondary and tertiary strategies for preventing metabolic 
disturbances in cases at higher risk.    
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Abstract:   
Though weight gain is a common side effect of antipsychotic treatment, there are 
no useful predictors of which patients are likely to be affected and to what de-
gree. It has been shown that exposure to adverse conditions during intra-uterine 
life confers a vulnerability to the development of later life metabolic complications 
and low birth weight for gestational age has been shown to be a robust marker of 
such prenatal adversity. We hypothesized that patients with schizophrenia with a 
lower birth weight will have increased vulnerability to the weight inducing effects 
of antipsychotic treatment. The relationship between birth weight and total and 
central adiposity, measured as body mass index (BMI) and waist-to-hip ratio 
(WHR) respectively, was examined in three groups: drug naïve first episode of 
psychosis (FEP) patients (n=41), treatment resistant schizophrenia (TRS) pa-
tients (n=42) and matched healthy volunteers (n=72). All analyses were con-
trolled for age, gender and duration of treatment exposure. We found that a lower 
birth weight was associated with higher BMI and WHR only in TRS patients but 
not in FEP or controls, suggesting that prenatal adversity, as indicated by the 
surrogate marker of a lower birth weight, confers an increased vulnerability to 
clozapine induced weight gain.  
 
 
 
Key words:  Birth weight, developmental programming, clozapine, schizophre-
nia, weight gain, first episode psychosis. 
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Introduction 
Up to 75% of patients taking antipsychotic for schizophrenia gain excessive 
weight (NICE, 2014). This has important implications for treatment compliance 
and health of a patient group that already has an average life expectancy 16-25 
years less than the general population (Saha et al., 2007). A major limitation is 
the paucity of effective treatments for this weight gain or reliable predictors of 
who is more likely to gain weight on these treatments and to what degree 
(Fernandez-Egea et al., 2011). 
Low birth weight for gestational age, a surrogate marker of intra-utero growth 
stress, is a risk factor common to both schizophrenia (Cannon et al., 2002) and 
metabolic disease (Cottrell and Ozanne, 2008). Studies of the Dutch Hunger 
Winter and the Chinese famine showed that individuals who experienced caloric 
deprivation during intra-uterine life, and consequently were born with low birth 
weight, were at greater risk for developing both metabolic disorders and schizo-
phrenia (Susser and St Clair, 2013). The role of suboptimal prenatal environment 
in the development of metabolic and cardiovascular disease has been extensive-
ly studied and it is now widely recognised that adversity during fetal life, caused 
by for example placental insufficiency or maternal malnutrition, triggers various 
fetal adaptations as a predictive adaptive response in anticipation of similar con-
ditions in postnatal life (Hales and Barker, 2001). These include the sparing of 
vital organs such as the brain at the expense of other organs such as the pan-
creas, and are protective for immediate postnatal survival and remain so if the 
postnatal environment is similar (Barnes and Ozanne, 2011). While the individual 
may have small abnormalities in the cardiovascular and metabolic systems such 
as mildly elevated blood pressure or impaired glucose tolerance, it is 
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when the postnatal environment does not match the predicted one, for example 
with widespread availability of calorie rich food, that these adaptations increase 
the risk for the development of obesity, type 2 diabetes and hypertension.  
While this model has been extensively studied in animal models and human pop-
ulation studies (Bann et al., 2014; Eriksson et al., 2001), there has been little ex-
ploration of the possible association of schizophrenia and obesity as part of a 
shared developmental programming effect (Garcia-Rizo et al., 2014). Subtle 
metabolic abnormalities such as glucose dysregulation (Fernandez-Egea et al., 
2009) and increased intra-abdominal fat (Thakore et al., 2002) have been de-
scribed in drug naive psychotic patients, and these would be consistent with such 
a programming effect.  
We hypothesized that in schizophrenia, birth weight is a marker of a vulnerability 
to weight gain and metabolic complications (See Figure 1). This vulnerability in-
teracts with an environmental factor, namely antipsychotic treatment, resulting in 
the development of excessive adiposity in those individuals with a lower birth 
weight. To test this hypothesis, we examined two patient groups with schizophre-
nia and a matched healthy control group. The two patient groups were treatment 
naive first episode non-affective psychosis patients (with diagnosis, no treatment) 
and treatment resistant patients (with diagnosis, on treatment) on clozapine, 
which has one of the highest propensities to induce weight gain, second only to 
olanzapine (Leucht et al., 2013). Our aim was to examine if birth weight modulat-
ed the degree of development of weight gain in response to antipsychotic treat-
ment. 
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Experimental Procedures 
The study was conducted using data from two clinical databases described else-
where, the 'Diabetes in neuropsychiatric disorders' database for drug naive first 
episode psychosis (FEP) patients at Hospital Clinic in Barcelona, Spain 
(Fernandez-Egea et al., 2009), and the ‘Clinical and Research Database in Per-
sistent Schizophrenia’ in the Cambridgeshire and Peterborough Foundation NHS 
Trust Mental Health in the UK (www.psychiatry.cam.ac.uk/f20). Informed consent 
was taken from participants prior to inclusion in the databases. Ethical approval 
to collect the patient data was granted by the Hospital Clinic Ethics Committee 
(Barcelona) and the NRES Cambridge Central Research Ethics Committee 
(13/EE/0121).  
Birth weight was collected as part of the study protocol for the FEP patients and 
clinical routine practice for TRS patients. Birth weight data were self-reported and 
only included if verified by a parent or if the patient reported the same birth 
weight at a minimum of two separate consultations. All participants from the two 
databases for whom a reliable birth weight was available were included and this 
was the only inclusion criterion. Clinical and anthropometric data were collected 
from the research project for the FEP and healthy control groups and the clinical 
notes and routine physical monitoring that all TRS patients undergo. Data on sex, 
age, height, current weight and waist and hip circumference, were collected on all 
individuals by observers blind to the status of the birth weigh information. Body 
Mass Index (BMI) and waist-to-hip ratio (WHR) were derived from the anthropo-
metric data. All subjects had data on either BMI or WHR. The included partici-
pants did not differ from those on whom no birth weight data were available in 
terms of their BMI or WHR. For the TRS patients data on the duration and 
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dose of antipsychotic treatment, use of other drugs affecting weight (e.g. 
mirtazapine), known metabolic complications and smoking status, were obtained 
from the clinical notes. All TRS patients were on clozapine with the exception of 
one on high-dose olanzapine.  
Statistical Analyses: All analyses were carried out using linear regression (lm 
package in R). The primary analyses tested the hypothesis that the relationship 
between birth weight and adult adiposity would only be seen in patients exposed 
to antipsychotic treatment. The model included birth weight, group and a birth 
weight x group interaction. The group variable contains the treatment effect: con-
trols (no diagnosis, no treatment), FEP (diagnosis present, no treatment) and 
TRS (diagnosis present, treatment present). However FEP and TRS groups may 
vary in other respects so the group variable was coded as a factor with 3 levels 
and not as a continuous variable as this approach makes fewer assumptions 
about the relationship between the groups. Treatment duration, age and gender 
were included as covariates as the groups differed significantly in terms of age 
and the sample had more males than females. Treatment duration was chosen 
as the measure of total antipsychotic exposure and calculated as the total dura-
tion of treatment from the first initiation of antipsychotic treatment. The primary 
analyses were carried out separately for the dependent variables of BMI and 
WHR and a Bonferroni correction was applied.  
Two secondary analyses were carried out in the TRS group alone. In the primary 
analyses the TRS factor includes both diagnosis and treatment variables and it is 
not possible to separate these. To explore this further the secondary analyses 
examined the relationship between birth weight and the adiposity measures after 
controlling for treatment exposure (treatment duration). Age, gender and 
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smoking status (associated with lower clozapine plasma levels) were included as 
covariates and BMI and WHR were examined as separate dependent variables 
and a Bonferroni correction was applied.  
 
Results 
The final sample included only subjects on whom reliable data on birth weight 
was available. This included 41 drug naive FEP patients from Barcelona (out of 
92 included in the database), 42 individuals with TRS from the UK (out of 152 
patients) and 72 healthy controls from both UK and Spain (out of 135 recruited). 
The overall sample characteristics are shown in Table 1.  
There was a strong correlation between BMI and WHR across the whole sample 
(r =0.59, p<0.0001). The correlation between age and birth weight was examined 
to check for potential collinearity and was found to be nonsignificant (r=0.11, 
p=0.17). After controlling for age, sex and treatment duration, there was a signifi-
cant effect of TRS group status on BMI (T=6.06, p<0.0001), with TRS status be-
ing associated with higher BMI. There was a significant negative TRS group x 
birth weight interaction (T=-3.78,p=0.0002) i.e. a unit increase in birth weight pro-
duces a corresponding decrease in adult BMI. For the WHR analysis, there was 
a significant effect of TRS group (T=2.88, p=0.0046) but the birth weight x treat-
ment interaction term did not reach significance (T=-1.72,p=0.087). The signifi-
cant effect of TRS group status was investigated further in the secondary anal-
yses. Lower birth weight in TRS patients was significantly associated with greater 
BMI (T=-2.38,p=0.023) and WHR (T=-2.51,p=0.017). These associations re-
mained even if the one TRS patient on high dose olanzapine was removed from 
the sample. There was no effect of smoking status on these associations.  
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Discussion 
We found that a lower birth weight was significantly associated with adiposity in 
TRS patients. This association was not found in drug naive patients and healthy 
volunteers, suggesting that the metabolic consequences of developmental pro-
gramming only become grossly apparent after exposure to an additional insult, in 
this case antipsychotic treatment, and it modulates the degree of weight gain and 
fat distribution in response to the treatment.  
We hypothesized that in schizophrenia, antipsychotic treatment represented the 
key environmental factor that interacts with this vulnerability, especially as it is like-
ly that all individuals in the current study will already have had a significant exposure to a 
similar environment (occidental caloric rich food environment).. In our study there was 
no difference in birth weight between the three groups. There was no effect of 
lower birth weight on adiposity in un-medicated individuals (controls and FEP 
patients). In these groups BMI and WHR were associated with age and gender 
but it is only in the TRS group that we saw an effect of a lower birth weight, sug-
gesting that antipsychotic medication may be the environmental factor that un-
masks this vulnerability. 
Our findings are novel in the field of schizophrenia, but are in line with a large 
body of evidence in metabolic science that shows that low birth weight (as a 
marker of prenatal adversity) is associated with later life obesity and metabolic 
disease, especially when associated with a second “hit” such as postnatal over-
nutrition (Ozanne et al., 2004). Patients with schizophrenia treated with antipsy-
chotics represent a particular case in this model of obesity with intra-
  
9 
uterine stressors conferring vulnerability to developing both schizophrenia and 
metabolic complications, with both conditions probably developing in response to 
additional factors. Recent evidence shows that severe prenatal stress in mice 
confers vulnerability for developing both metabolic and neural disturbances, the 
latter manifest as abnormalities in prepulse inhibition (PPI) abnormalities, a pre-
attentive process known to be impaired in schizophrenia (Pacheco-Lopez et al., 
2011). Subtle metabolic abnormalities have been described in schizophrenia in 
drug naive patients, such as increased visceral fat (Thakore et al., 2002) or 
prediabetes (Fernandez-Egea et al., 2009). Interestingly, these are subclinical 
abnormalities that were only observed when using more precise tools (such as 
CT scan or glucose tolerance tests). This is in keeping with the idea that they 
represent vulnerability traits rather than overt disorders.   
Our findings add to the accumulating evidence suggesting that a lower birth 
weight is not only a risk factor for developing schizophrenia (Cannon et al., 2002) 
but is also associated with a poorer prognosis. Low birth weight is a predictor of 
poorer cognitive functioning (Torniainen et al., 2013); it has been associated with 
smaller cortical area (Haukvik et al., 2014), more severe clinical symptomatology 
and attentional impairment (Wegelius et al., 2013). This cross-sectional study 
cannot adequately address this. While the distribution of birth weight in the three 
groups is very similar, there is the possibility that patients with first episode psy-
chosis with a lower birth weight may go on to develop a more severe form of the 
illness. However what we do find is that even if we consider only patients who 
have reached the stage of treatment resistance, there is a clear relationship be-
tween a lower birth weight and adiposity. 
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Our results also suggest that birth weight might be a useful predictor of antipsy-
chotic induced weight gain. A more comprehensive model should include genetic 
(Shungin et al., 2015) as well as neurodevelopmental information (birth weight), 
environmental factors (i.e. antipsychotic medication), and behavioural factors (i.e. 
sedentarism). Birth weight could be a rapidly accessible measure than could help 
clinicians to predict who will be at greater risk for weight gain and/or will need 
more regular physical health checks. However a larger longitudinal study will be 
required to provide a more robust quantification of the effect of birth weight on 
future weight gain that could be used reliably in the clinic. It would also be im-
portant to examine if this effect is seen with other antipsychotics apart from 
clozapine.  
We acknowledge some limitations to our study. Lower birth weight was consid-
ered exclusively as a surrogate marker of intra-utero stress, but this is not the 
only possible cause of low birth weight. We did not examine the potential role of  
adverse childhood experiences and this might require further study in the future. 
The sample size is relatively small and the main dependent variable was ob-
tained by self-report. However, where possible the birth weight data were corrob-
orated by collateral history from a parent and in all other instances data were only 
included if the self-report was consistent across a minimum of two consultations. 
Importantly, birth weight data were collected in the same way for all 3 groups. 
There was a significant age difference between the TRS and the other groups 
and while we controlled for age in all analyses, given the difference in age distri-
bution across the groups, its contribution cannot be reliably determined by co-
varying for it in our statistical models. However, the effect of birth weight on adi-
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posity in the TRS group was seen in total fat (BMI) and also in the central fat dis-
tribution (WHR), being the latter being less associated with age. Duration of 
treatment exposure is an important factor in these analyses. Ideally one should 
examine total cumulative antipsychotic exposure but we did not have sufficient 
data from clinical records or clozapine plasma levels to estimate this. We there-
fore calculated treatment exposure as the time from first initiation of antipsychotic 
to the present. This variable does not account for dosage, periods of non-
compliance or treatment cessation and does not capture the number of different 
drugs prescribed. However for the purposes of this analysis it is likely to exag-
gerate the effect of antipsychotic treatment (i.e. as per the variable all individuals 
have been on clozapine for their entire treatment history) in the models and re-
duces the chances of detecting a birth weight effect. This variable also captures 
duration of illness and assumes that individuals have been continuously ill since 
first initiation of treatment. Given that we are studying a trait and not state vulner-
ability, we believe that this is a reasonable assumption. Finally, the study is 
cross-sectional as a prospective longitudinal study to test these hypotheses 
would be extremely challenging to carry out, as it should ideally include drug na-
ive patients followed up for a number of years. Nevertheless the limitations of 
cross-sectional designs remain but replication of this association in larger sam-
ples such as well-described cohorts would help corroborate our findings.   
In conclusion, our study suggests that birth weight, as a measure of intra-uterine 
adversity, modulates the susceptibility to antipsychotic induced weight gain. 
Though one must be cautious given the small sample size and cross-sectional 
design of this study, it does accord with the paradigm that considers schizophre-
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nia not just as a brain disorder but also as a whole body-disease (Khandaker et 
al., 2014; Kirkpatrick et al., 2014). Indeed early life stress been theoretically de-
scribed as a risk factor for both, mental and metabolic disorders over time, in this 
model metabolic disturbances are a constitutive part of the disorder (Garcia-Rizo 
et al., 2014), expressed at a later stage but earlier than the general population 
(Kirkpatrick et al., 2008). This might also help revise our interpretation of the early 
morbidity and mortality associated with schizophrenia (Laursen et al., 2014) and 
promote the use of secondary and tertiary strategies for preventing metabolic 
disturbances in cases at higher risk.    
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Highlights 
 
Birth weight modulates clozapine associated weight gain.  
 
Total fat and central fat distribution was higher in those with lower birth 
weight.  
 
This association is not seen in drug naïve psychosis or matched controls. 
 
 
 
 
highlights
  
Table 1: Sample characteristics 
All data are presented as mean ± standard deviation (range).  All significant differences are between the TRS group and the others. The 
only difference between FEP and controls is in the BMI where there is a small negative effect (parameter estimate -1.58, p = 0.042). 
 
 
 TRS FEP Controls Difference 
N 42 41 72  
Age 40.45 ± 8.84 
(23-59) 
27.6  ± 6.1 
(19-45) 
28.96 ± 7 
(19-50) 
<0.0001* 
Sex 31M: 11F 25M: 16F 42M: 30F  
Birth weight 3.45 ± 0.65 
(2.26-5.1) 
3.31 ± 0.51 
(2.25-4.6) 
3.49 ± 0.52 
(2.1-4.62) 
n.s. 
WHR 0.967 ± 0.078 
(0.81-1.122) 
0.839 ± 0.067 
(0.66-0.979) 
0.858 ± 0.078 
(0.68-1.045) 
<0.0001* 
BMI 30.66  ± 4.63 
(21.9-41.3) 
22.3  ± 3.9 
(15.9-38.5) 
23.96 ± 3.55 
(18.89-33.14) 
<0.0001* 
Years on antipsychotic 
treatment 
18.7  ± 8.32 
 (5-41) 
   
Years on clozapine 10.65  ± 6.38 
(1-24) 
   
Clozapine dose (mg/day) 312.2 ± 118.47 
(125-600) 
   
 
 
 
 
 
Table(s)
  
Figure 1: Hypothesised simplified relationship between intra-uterine adversity and antipsychotic induced weight gain and metabolic 
complications 
 
 
 
Figure 1
  
Figure 2: Relationship between birth weight and Body Mass Index (BMI) across the groups (shaded intervals represent 95% confidence 
intervals) 
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Figure 3: Relationship between birth weight and Waist to Hip ratio (WHR) across the groups (shaded intervals represent 95% confidence 
intervals) 	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